Start with a 30-minute introduction call
No sales pitch—just honest assessment
Ready to discuss your pharma market entry strategy? Want to learn more about how I can help with your commercial growth or business optimization? Schedule a call. I'll help you understand where you are, what's realistic, and whether we're a fit to work together.
View My Calendar & Book a Time
Based in EU, flexible with US timezone for real-time collaboration when you need it.
Before the call: You'll receive a short questionnaire (3-5 questions) so I can prepare and make our time together valuable.
After the call: If we're aligned, I'll send a written proposal within 3-5 business days. You can review with your team, board, or investors before deciding.
I review all inquiries within 24 hours. If it looks like a potential fit, I'll respond with some preliminary questions and calendar availability for our intro call. If timing or fit isn't right, I'll let you know honestly.
Yes, I'm happy to sign mutual NDAs before discussing proprietary technology or business strategy. I take confidentiality seriously and can provide references from previous clients.
Engagements are project-based with clear deliverables and milestones. Pricing depends on scope and timeline. For example, a Market Readiness Assessment starts around €7,500; Comprehensive Strategy engagements range from €60,000-€125,000 in phased investments. Fractional CxO retainers can range €8,000-€15,000/month. I provide detailed proposals after our initial conversation so you know exactly what you're getting.
The introductory call is complimentary. For paid single-session consultations, I offer 90-minute deep-dive advisory sessions at €750 per session, ideal for specific questions or second opinions.
Absolutely. I'm based in the EU with deep expertise in European regulatory requirements (EMA, GDPR, DACH markets). I'm bilingual (English/German C1) and work flexibly across US and EU timezones.
I work with health tech companies from early-stage (pre-revenue, preparing for first pharma pilots) through growth-stage (Series A+, scaling commercial operations). The common thread is they're all selling into pharmaceutical R&D and clinical trials.
I typically work with 2-4 clients simultaneously. If I'm at capacity, I maintain a waitlist and can provide referrals to trusted colleagues. As of Jan 2026, I can accept 1 new client. Additional availability expected by May 2026.